

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
VI/00-012

In Re Application Of: COWAN, et al.

Serial No.
09/765,498

Filing Date
1/18/2001

Examiner
Matthew F. DeSanto

Group Art Unit
3763

Title: ENCODING AND SENSING OF SYRINGE INFORMATION

RECEIVED
JAN 16 2004
TECHNOLOGY CENTER R3700

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.


37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
VI/00-012

In Re Application: COWAN, et al.



Serial No.

09/765,498

Filing Date

1/18/2001

Examiner

Matthew F. DeSanto

Group Art Unit

3763

ENCODING AND SENSING OF SYRINGE INFORMATION

RECEIVED
JAN 16 2004
TECHNOLOGY CENTER R3700

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate


*This certificate may only be used if paying by deposit account.

Signature

Gregory L. Bradley
MEDRAD, INC.
One Medrad Drive
Indianola, PA 15051

Dated: January 12, 2004

CC:



Atty. Docket No.: VI/00-012

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

COWAN et al.

Serial No.: 09/765,498

Filed: January 18, 2001

Title: ENCODING AND SENSING OF SYRINGE
INFORMATION

Art Unit: 3763

Examiner: Matthew F. DeSanto

RECEIVED
JAN 16 2004
TECHNOLOGY CENTER R3700

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98. The items listed on the attached Forms PTO-1449 may be deemed to be relevant to the patentability of the above-identified application, and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

Redacted Declaration of Thomas H. Braunstein

The Redacted Declaration of Thomas Braunstein ("Declaration") is submitted herewith as item AJ on the accompanying Forms PTO-1449. The Declaration was submitted during patent litigation, styled Liebel-Flarsheim Company v. Medrad, Inc., in the United States District Court for the Southern District of Ohio.

The Declaration, inter alia, explains the syringe encoding system commercialized in Medrad's Envision CT™ and Medrad Vistron CT® injector and syringe systems, which corresponds to the encoding system described in U.S. Patent No. 5,944,694 to Hitchins et al., which was applied by the Examiner against various claims pending in this application.

Co-pending Applications

Applicant wishes to bring a number of co-pending applications to the Examiner's attention. These applications are directed to encoding and sensing of syringe information and may contain subject matter related to that disclosed and/or claimed in the present application.


- U.S. Pat. App. Publ. No. 2003-0065287, filed on April 2, 2002, and
- U. S. Serial Number 10/466,418, filed on July 16, 2003.

The Examiner is respectfully requested to initial the attached Forms PTO-1449 to indicate consideration of the references, and to return copies of the initialed forms to the undersigned counsel.

This Information Disclosure Statement is being filed with a Request for Continued Examination, and NO FEE is due for its consideration.

Date: January 12, 2004

Respectfully submitted,



Gregory L. Bradley
Reg. No. 34,299

Medrad, Inc.
One Medrad Drive
Indianola, PA 15051
(412) 767-2400 x3021

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Mailing Label No. EV207494297US. Date of Deposit: January 12, 2004. I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office To Addressee" Service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dawn M. Dedola

